Cargando…
Clinically Approved Heterocyclics Act on a Mitochondrial Target and Reduce Stroke-induced Pathology
Substantial evidence indicates that mitochondria are a major checkpoint in several pathways leading to neuronal cell death, but discerning critical propagation stages from downstream consequences has been difficult. The mitochondrial permeability transition (mPT) may be critical in stroke-related in...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2212009/ https://www.ncbi.nlm.nih.gov/pubmed/15263028 http://dx.doi.org/10.1084/jem.20032053 |
_version_ | 1782148602950320128 |
---|---|
author | Stavrovskaya, Irina G. Narayanan, Malini V. Zhang, Wenhua Krasnikov, Boris F. Heemskerk, Jill Young, S. Stanley Blass, John P. Brown, Abraham M. Beal, M. Flint Friedlander, Robert M. Kristal, Bruce S. |
author_facet | Stavrovskaya, Irina G. Narayanan, Malini V. Zhang, Wenhua Krasnikov, Boris F. Heemskerk, Jill Young, S. Stanley Blass, John P. Brown, Abraham M. Beal, M. Flint Friedlander, Robert M. Kristal, Bruce S. |
author_sort | Stavrovskaya, Irina G. |
collection | PubMed |
description | Substantial evidence indicates that mitochondria are a major checkpoint in several pathways leading to neuronal cell death, but discerning critical propagation stages from downstream consequences has been difficult. The mitochondrial permeability transition (mPT) may be critical in stroke-related injury. To address this hypothesis, identify potential therapeutics, and screen for new uses for established drugs with known toxicity, 1,040 FDA-approved drugs and other bioactive compounds were tested as potential mPT inhibitors. We report the identification of 28 structurally related drugs, including tricyclic antidepressants and antipsychotics, capable of delaying the mPT. Clinically achievable doses of one drug in this general structural class that inhibits mPT, promethazine, were protective in both in vitro and mouse models of stroke. Specifically, promethazine protected primary neuronal cultures subjected to oxygen-glucose deprivation and reduced infarct size and neurological impairment in mice subjected to middle cerebral artery occlusion/reperfusion. These results, in conjunction with new insights provided to older studies, (a) suggest a class of safe, tolerable drugs for stroke and neurodegeneration; (b) provide new tools for understanding mitochondrial roles in neuronal cell death; (c) demonstrate the clinical/experimental value of screening collections of bioactive compounds enriched in clinically available agents; and (d) provide discovery-based evidence that mPT is an essential, causative event in stroke-related injury. |
format | Text |
id | pubmed-2212009 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | The Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-22120092008-03-11 Clinically Approved Heterocyclics Act on a Mitochondrial Target and Reduce Stroke-induced Pathology Stavrovskaya, Irina G. Narayanan, Malini V. Zhang, Wenhua Krasnikov, Boris F. Heemskerk, Jill Young, S. Stanley Blass, John P. Brown, Abraham M. Beal, M. Flint Friedlander, Robert M. Kristal, Bruce S. J Exp Med Article Substantial evidence indicates that mitochondria are a major checkpoint in several pathways leading to neuronal cell death, but discerning critical propagation stages from downstream consequences has been difficult. The mitochondrial permeability transition (mPT) may be critical in stroke-related injury. To address this hypothesis, identify potential therapeutics, and screen for new uses for established drugs with known toxicity, 1,040 FDA-approved drugs and other bioactive compounds were tested as potential mPT inhibitors. We report the identification of 28 structurally related drugs, including tricyclic antidepressants and antipsychotics, capable of delaying the mPT. Clinically achievable doses of one drug in this general structural class that inhibits mPT, promethazine, were protective in both in vitro and mouse models of stroke. Specifically, promethazine protected primary neuronal cultures subjected to oxygen-glucose deprivation and reduced infarct size and neurological impairment in mice subjected to middle cerebral artery occlusion/reperfusion. These results, in conjunction with new insights provided to older studies, (a) suggest a class of safe, tolerable drugs for stroke and neurodegeneration; (b) provide new tools for understanding mitochondrial roles in neuronal cell death; (c) demonstrate the clinical/experimental value of screening collections of bioactive compounds enriched in clinically available agents; and (d) provide discovery-based evidence that mPT is an essential, causative event in stroke-related injury. The Rockefeller University Press 2004-07-19 /pmc/articles/PMC2212009/ /pubmed/15263028 http://dx.doi.org/10.1084/jem.20032053 Text en Copyright © 2004, The Rockefeller University Press This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/). |
spellingShingle | Article Stavrovskaya, Irina G. Narayanan, Malini V. Zhang, Wenhua Krasnikov, Boris F. Heemskerk, Jill Young, S. Stanley Blass, John P. Brown, Abraham M. Beal, M. Flint Friedlander, Robert M. Kristal, Bruce S. Clinically Approved Heterocyclics Act on a Mitochondrial Target and Reduce Stroke-induced Pathology |
title | Clinically Approved Heterocyclics Act on a Mitochondrial Target and Reduce Stroke-induced Pathology |
title_full | Clinically Approved Heterocyclics Act on a Mitochondrial Target and Reduce Stroke-induced Pathology |
title_fullStr | Clinically Approved Heterocyclics Act on a Mitochondrial Target and Reduce Stroke-induced Pathology |
title_full_unstemmed | Clinically Approved Heterocyclics Act on a Mitochondrial Target and Reduce Stroke-induced Pathology |
title_short | Clinically Approved Heterocyclics Act on a Mitochondrial Target and Reduce Stroke-induced Pathology |
title_sort | clinically approved heterocyclics act on a mitochondrial target and reduce stroke-induced pathology |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2212009/ https://www.ncbi.nlm.nih.gov/pubmed/15263028 http://dx.doi.org/10.1084/jem.20032053 |
work_keys_str_mv | AT stavrovskayairinag clinicallyapprovedheterocyclicsactonamitochondrialtargetandreducestrokeinducedpathology AT narayananmaliniv clinicallyapprovedheterocyclicsactonamitochondrialtargetandreducestrokeinducedpathology AT zhangwenhua clinicallyapprovedheterocyclicsactonamitochondrialtargetandreducestrokeinducedpathology AT krasnikovborisf clinicallyapprovedheterocyclicsactonamitochondrialtargetandreducestrokeinducedpathology AT heemskerkjill clinicallyapprovedheterocyclicsactonamitochondrialtargetandreducestrokeinducedpathology AT youngsstanley clinicallyapprovedheterocyclicsactonamitochondrialtargetandreducestrokeinducedpathology AT blassjohnp clinicallyapprovedheterocyclicsactonamitochondrialtargetandreducestrokeinducedpathology AT brownabrahamm clinicallyapprovedheterocyclicsactonamitochondrialtargetandreducestrokeinducedpathology AT bealmflint clinicallyapprovedheterocyclicsactonamitochondrialtargetandreducestrokeinducedpathology AT friedlanderrobertm clinicallyapprovedheterocyclicsactonamitochondrialtargetandreducestrokeinducedpathology AT kristalbruces clinicallyapprovedheterocyclicsactonamitochondrialtargetandreducestrokeinducedpathology |